Margraf, Nils G. http://orcid.org/0000-0003-2197-1079
Dargvainiene, Justina
Theel, Emily
Leypoldt, Frank
Lieb, Wolfgang
Franke, Andre
Berger, Klaus
Kuhle, Jens
Kuhlenbaeumer, Gregor
Funding for this research was provided by:
Universitätsklinikum Schleswig-Holstein - Campus Kiel
Article History
Received: 2 October 2022
Revised: 22 December 2022
Accepted: 23 December 2022
First Online: 9 January 2023
Declarations
:
: NGM received travel grants from Eisai Pharma and Angelini Pharma. Lecture fees were given by Jazz Pharma and Angelini Pharma. Research support was granted by Jazz Pharma, Angelini Pharma, Eisai Pharma, UCB Pharma, LivaNova and Desitin Pharma. He also receives funding from the Ministry of Health (Schleswig–Holstein) and the German Research Council (DFG). Non-financial interests: none. JD has no relevant financial or non-financial interests to disclose. ET has no relevant financial or non-financial interests to disclose. FL reports having received speaker’s honoraria from Grifols, Biogen, Novartis, Roche, Alexion, serving on advisory boards for Roche and Biogen and receiving research funding from the German Ministry of Education and Research, the German Society for Laboratory Medicine (DGKL) and the German Research Council (DFG). He works for an academic institution offering commercial autoantibody testing. Non-financial interests: none. WL has no relevant financial or non-financial interests to disclose. AF has no relevant financial or non-financial interests to disclose. KB receives for the MEMO Study funding by the German Research Society (Deutsche Forschungsgemeinschaft DFG, grant: BE1996/1-1). The measurement of NfL was done through funds from the Institute of Epidemiology and Social Medicine, University of Muenster. The BiDirect Study is supported by grants of the German Ministry of Research and Education (BMBF) to the University of Muenster (01ER0816 and 01ER1506). Non-financial interests: none. JK received speaker fees, research support, travel support, and/or served on advisory boards by Swiss MS Society, Swiss National Research Foundation (320030_189140/1), University of Basel, Progressive MS Alliance, Bayer, Biogen, Bristol Myers Squibb, Celgene, Merck, Novartis, Octave Bioscience, Roche, Sanofi. Non-financial interests: none. GK receives non-project-related financial support from the BMBF project CONNECT-GENERATE: Genetics of autoimmune encephalitis. Non-financial interests: none. The authors declare that they have no conflict of interest concerning this work.
: The study was approved by the Ethics Committee of the Medical Faculty of the Christian-Albrechts-University, Kiel, Germany (D 480/20). The study was conducted following the World Medical Association Declaration of Helsinki. The use of retrospective data was reviewed and confirmed by the Ethics Committee. The data protection guidelines were also observed. The identity of the subjects is protected.